Choreo LLC Sells 35,671 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Choreo LLC reduced its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK) by 49.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,086 shares of the biotechnology company’s stock after selling 35,671 shares during the period. Choreo LLC’s holdings in OPKO Health were worth $55,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of OPK. SG Americas Securities LLC increased its holdings in OPKO Health by 1,086.9% in the 3rd quarter. SG Americas Securities LLC now owns 135,856 shares of the biotechnology company’s stock worth $202,000 after buying an additional 124,410 shares in the last quarter. Private Advisor Group LLC boosted its holdings in shares of OPKO Health by 242.7% during the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 25,000 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of OPKO Health by 142.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after acquiring an additional 876,272 shares during the last quarter. PFG Investments LLC grew its stake in shares of OPKO Health by 10.4% in the third quarter. PFG Investments LLC now owns 1,061,090 shares of the biotechnology company’s stock worth $1,581,000 after acquiring an additional 100,125 shares during the period. Finally, Highline Wealth Partners LLC purchased a new position in shares of OPKO Health during the third quarter valued at approximately $174,000. Institutional investors own 64.63% of the company’s stock.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost purchased 47,537 shares of the firm’s stock in a transaction on Tuesday, January 28th. The shares were acquired at an average price of $1.47 per share, for a total transaction of $69,879.39. Following the purchase, the chief executive officer now directly owns 213,234,014 shares in the company, valued at $313,454,000.58. This trade represents a 0.02 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders acquired 1,621,609 shares of company stock worth $2,472,710. 47.26% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on OPK. Barrington Research reiterated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research note on Friday, November 8th. StockNews.com cut OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research report on Wednesday, January 8th.

OPKO Health Trading Down 1.2 %

Shares of NASDAQ:OPK opened at $1.64 on Monday. The stock has a 50 day moving average of $1.53 and a 200 day moving average of $1.53. The company has a market cap of $1.12 billion, a PE ratio of -8.63 and a beta of 1.63. OPKO Health, Inc. has a 12-month low of $0.86 and a 12-month high of $1.76. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.